BACKGROUND Depression significantly threatens human health.Purinergic receptors are reported to be associated with depression.However,there is no bibliometric research in this field have been published.AIM To provide ...BACKGROUND Depression significantly threatens human health.Purinergic receptors are reported to be associated with depression.However,there is no bibliometric research in this field have been published.AIM To provide some reference for the further research in the field of purinergic receptors and depression utilizing bibliometric analysis.METHODS Relevant researches were retrieved from the Web of Science Core Collection database.The period of the search was from January 1,2003 to December 31,2023.The CiteSpace(6.2.R7)and VOSviewer(1.6.19)were applied to identify the main contributors of countries,authors,institutions,references and journals.Besides,we evaluate keywords to assess the hotspots and trends over the previous 2 decades.RESULTS Totally,247 articles were identified,showing an increasing trend over time.The most productive country,institution,and journal in this field are China,Harvard University,and Biological Psychiatry,respectively.Liang SD and Rodrigues,Ana Lucia S were the most prolific authors.Burnstock G ranked first among the cited authors.The cooperation among countries and disciplines is crucial.The P2X7 receptor provides promising prospects for treating depression and further studies are warranted to validate the scope and significance of depression therapeutic strategies.CONCLUSION This study provides an overview of the worldwide research status and future trends in purinergic receptors and depression.P2X7 receptor is considered an appropriate target for the treatment of depression,as well as neurological diseases.It is implied that based on purinergic system,the future prospects for interventions aimed at depression treatment are promising,showing the way for both augmentation strategies and new drug treatments in the context of the pharmacology of depression.展开更多
基金Supported by the National Key Research and Development Program of China,No.2019YFC1709703Jiangxi Provincial Science and Technology Department,No.20212BAG70037+1 种基金Jiangxi Provincial Education Department Science Program,No.GJJ201259Jiangxi Provincial Administration of Traditional Chinese Medicine,No.2021B324.
文摘BACKGROUND Depression significantly threatens human health.Purinergic receptors are reported to be associated with depression.However,there is no bibliometric research in this field have been published.AIM To provide some reference for the further research in the field of purinergic receptors and depression utilizing bibliometric analysis.METHODS Relevant researches were retrieved from the Web of Science Core Collection database.The period of the search was from January 1,2003 to December 31,2023.The CiteSpace(6.2.R7)and VOSviewer(1.6.19)were applied to identify the main contributors of countries,authors,institutions,references and journals.Besides,we evaluate keywords to assess the hotspots and trends over the previous 2 decades.RESULTS Totally,247 articles were identified,showing an increasing trend over time.The most productive country,institution,and journal in this field are China,Harvard University,and Biological Psychiatry,respectively.Liang SD and Rodrigues,Ana Lucia S were the most prolific authors.Burnstock G ranked first among the cited authors.The cooperation among countries and disciplines is crucial.The P2X7 receptor provides promising prospects for treating depression and further studies are warranted to validate the scope and significance of depression therapeutic strategies.CONCLUSION This study provides an overview of the worldwide research status and future trends in purinergic receptors and depression.P2X7 receptor is considered an appropriate target for the treatment of depression,as well as neurological diseases.It is implied that based on purinergic system,the future prospects for interventions aimed at depression treatment are promising,showing the way for both augmentation strategies and new drug treatments in the context of the pharmacology of depression.
